Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients

Journal of Infectious Diseases

Volumn 187, Issue 6, 2003, Pages 879-886

  Ackers, Marta Louise ^a   Parekh, Bharat ^b   Evans, Thomas G ^c,e,f   Berman, Phillip ^d   Phillips, Susan ^b   Allen, Mary ^e   McDougal, J Steven ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d VaxGen Inc   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RECOMBINANT VACCINE; SMALLPOX VACCINE; SUBUNIT VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

ADULT; ANTIBODY DETECTION; ARTICLE; CANARYPOX VIRUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEROLOGY; WESTERN BLOTTING;

ADOLESCENT; ADULT; AIDS VACCINES; BLOTTING, WESTERN; CANARYPOX VIRUS; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV SEROPOSITIVITY; HIV-1; HUMANS; MIDDLE AGED; RECOMBINATION, GENETIC; UNITED STATES; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0037443948     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368169     Document Type: Article

References (33)

1. Esparaza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, where, when, and how? Lancet 2000; 355:2061-6.
2. Harro C, Judson F, Brown SJ, et al. Conduct of the first phase III efficacy trial of a preventive HIV-1 (AIDSVAX B/B) in North America and Europe [abstract WeOrD1299]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, July 2002; 2:149.
3. Choopanya K, Tappero J, Pitisuttithum P, et al. Ongoing follow-up of injecting drug users (IDUs) in the AIDSVAX B/E vaccine efficacy trial in Bangkok, Thailand [abstract WeOrD1300]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, July 2002; 2:149.
4. Evans TG, Keefer MC, Belshe RB, et al. Rates and determinants of positive HIV screening test results in uninfected participants in phase I/II trials of candidate HIV-1 vaccines [abstract 293]. In: Program and abstracts of the 1999 National HIV Prevention Conference (Atlanta). Atlanta, GA: Centers for Disease Control and Prevention, August 1999.
5. Belshe RB, Clements ML, Keefer MC, et al. Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. Ann Intern Med 1994; 121:584-9.
6. Allen M, Israel H, Rybczyk K, et al. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses 2001; 17:667-74.
7. Parekh B, Phillips S, George JR. Evaluation of commercial HIV diagnostic assays to discriminate serologic response of candidate AIDS vaccine recipients from that of HIV-infected individuals. AIDS Res Hum Retroviruses 1994; 10:S34.
8. Eastman D, Sheppard HWC, Dondero D, et al. Evaluation of commercial HIV diagnostic assays with sera obtained from volunteers immunized with recombinant gp120-based subunit vaccines [abstract MoPeA2135]. In: Program and abstracts of the XIII International AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, July 2000:45.
9. Schwartz DH, Laeyendecker OB, Arango-Jaramillo S, Castillo RC, Reynolds MJ. Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of a false-positive PCR. Lancet 1997; 350:256-9.
10. Serwanga J, Kaleebu P, Mugerwa R, et al. HIV-1 vaccine trial in Uganda: experience on pre- and post-vaccination screening of volunteers [abstract WeOrC557]. In: Program and abstracts of the XIII International AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, July 2000; 2:106.
11. Check E. Army HIV vaccine to undergo clinical trial as rival is halted. Nature 2002; 416:6.
12. Kahn P. International AIDS Vaccine Initiative (IAVI) outlines R&D plans for next two years. International AIDS Vaccine Initiative (IAVI) Report. New York, NY: IAVI, 2002; 6:6.
13. AIDS Vaccine Evaluation Group (AVEG)/HIV Vaccine Trails Network (HVTN) protocol outlines. Available at: http://www.hvtn.org/trials/outlines.sht. Accessed 23 October 2002.
14. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults. AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002; 29:254-61.
15. Mayer K, Judson F, Gorse G, et al. A phase I/II trial to evaluate the safety and immunogenicity of the AIDSVAX B/B vaccine in the United States (final report) [abstract 178]. In: Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
16. Judson FN, Mayer K, Gorse GJ, et al. Safety and immunogenicity evaluation of HIV-1 vaccines AIDSVAX B/B and AIDSVAX B/E: preliminary results [abstract WePpA1363]. In: Program and abstracts of the XIII International AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, July 2000; 2:14.
17. Centers for Disease Control and Prevention. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep 1989; 38(Suppl 7):1-7.
18. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep 2001; 50(RR-19):1-57.
19. Gross M, Seage GR, Mayer KH, Goldstein RS, Losina E, Wold C. Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:406-12.
20. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998; 12:785-93.
21. MacQueen KM, Buchbinder SP, Douglas JM, Judson FN, McKirnan DJ, Bartholow BN. Required HIV antibody testing, social risk, and HIV-vaccine efficacy trials. AIDS Public Policy J 1996; 11:104-12.
22. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:266-71.
23. Sheon A, Wagner L, McElrath MJ, et al. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J Acquir Immune Defic Synd Hum Retrovirol 1998; 19:519-26.
24. Bartholow BN, MacQueen KM, Douglas JM Jr, Buchbinder SP, McKirnan DJ, Judson FN. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:108-15.
25. Douglas JM, Judson FN, Parks J, Buchbinder SP, McKirnan DJ. Participation of homosexual/bisexual men in preventive HIV vaccine trials: Baseline attitudes and concerns and predicted behavior during trials. AIDS Res Hum Retroviruses 1994; 10(Suppl 2):S257-60.
26. Schultz AM, Bradac JA. The HIV vaccine pipeline, from preclinical to phase III. AIDS 2001; 15(Suppl 5):S147-58.
27. Cohen J. Monkey puzzles. Science 2002; 296:2325-6.
28. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999; 130:37-9.
29. de Mendoza C, Holguin A, Soriano V. False positives for HIV using commercial viral load quantification assays. AIDS 1998; 12:2076-7.
30. Havlichek DH Jr, Hage-Korban E. False-positive HIV diagnosis by HIV-1 plasma viral load testing. Ann Intern Med 1999; 131:794.
31. Kornman MT, Leparc G, Benson K. Nucleic acid amplification testing: the new infectious disease testing method for donor blood. Cancer Control 1999; 6:504-8.
32. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002; 42:1230-7.
33. Lee HH, Allain JP. Genomic screening for blood-borne viruses in transfusion settings. Vox Sang 1998; 74 (Suppl 2):119-23.